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Abstract
Primitive Gastrointestinal Lymphomas (PGIL) are uncommon tumours, although time-trend analyses have
demonstrated an increase. The role of surgery in the management of lymphoproliferative diseases has changed
over the past 40 years. Nowadays their management is centred on systemic treatments as chemo-/radio- therapy.
Surgery is restricted to very selected indications, always discussed in a multidisciplinary setting. The aim of this
systematic review is to evaluate the actual role of surgery in the treatment of PGIL.
A systematic review of literature was conducted according to the recommendations of The Cochrane
Collaboration. Main outcomes analysed were overall survival (OS) and disease free survival (DFS).
There are currently 1 RCT and 4 non-randomised prospective controlled studies comparing surgical versus medical
treatment for PGIL. Seven hundred and one patients were analysed, divided into two groups: 318 who underwent
to surgery alone or associated with chemotherapy and/or radiotherapy (surgical group) versus 383 who were
treated with chemotherapy and/or radiotherapy (medical group).
Despite the OS at 10 years between surgical and medical groups did not show relevant differences, the DFS was
significantly better in the medical group (P = 0.00001). Accordingly a trend was noticed in the recurrence rate, which was
lower in the medical group (6.06 vs. 8.57%); and an higher mortality was revealed in the surgical group (4.51% vs. 1.50%).
The chemotherapy confirms its primary role in the management of PGIL as part of systemic treatment in the
medical group. Surgery remains the treatment of choice in case of PGIL acutely complicated, although there is no
evidence in literature regarding the utility of preventive surgery.
Introduction
Primitive Gastrointestinal Lymphomas (PGIL) are uncom-
mon tumours, although time-trend analyses have demon-
strated an increase of 2.7% per annum in incidence for
gastric (6.3%) and small bowel diseases (5.9%) [1].
PGIL could be localised in any site of the gastrointestinal
tract [1-7]. The most frequent site is the stomach (44-
75%). Other locations might be the jejunum or the ileo-
cecal region, while duodenum, colon and rectum are rare.
Multiple gastrointestinal lesions are very infrequent.
The treatment of patient with PGIL is quite undefined.
In fact, although the efficacy of chemotherapy (CT) is
well recognised and all treatment strategies for PGIL
include CT, with or without radiotherapy (RT); whether
or not CT should be performed as unique medical treat-
ment or as part of a combined treatment, which includes
the surgical resection of the primary lymphoma, is still
discussed. Moreover, surgery is sometime necessary to
manage acute complications, such as haemorrhage,
abscess, gastrointestinal occlusion or perforation during
systemic therapies or suggested for prevention of such
emergencies.
The aim of this systematic review is to evaluate the
actual role of surgery in the treatment of PGIL, analysing
overall and disease free survival as main outcomes.
Methods of meta-analysis
We conducted the review according to the recommenda-
tions of The Cochrane Collaboration and performed the * Correspondence: cirocchiroberto@yahoo.it
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software.
Research methods for identification of studies
We searched for all published and unpublished randomised
controlled trials (RCT) and controlled clinical trials (CCT)
using the following electronic databases: Cochrane Central
Register of Controlled Trials, MEDLINE, Science Citation
Index, ISI Proceedings, Current Controlled Trials metaReg-
ister, Zetoc, CINAHL and EMBASE. The following medical
search headings (MeSH) and free text words were used:
“surgery’’; “chemotherapy”; “radiotherapy”; “gastric lym-
phoma"; ‘’gastrointestinal lymphoma”, “colonic lymphoma”.
We checked the reference lists of all relevant studies
obtained from our search and from previously published
systematic reviews in order to identify other possible arti-
cles. The latest date for this search was February 25
th 2010.
Data Extraction
Three authors (RC and ST) assessed titles or abstracts of
all the studies identified by the initial search and excluded
clearly non-relevant studies. They obtained the full text of
all potentially relevant studies and also those with unclear
methodology. These studies were assessed by the authors
as to whether they met the inclusion criteria for this
review. Disagreements on inclusion were resolved by dis-
cussing and, if necessary, by involving an independent
third author (EF).
Inclusion Criteria
To be included in the analysis, the studies had to com-
pare surgery alone or associated with chemotherapy and/
or radiotherapy (surgical group) versus chemotherapy
and/or radiotherapy (medical group) in the treatment of
gastrointestinal lymphoma tumours.
Exclusion Criteria
Studies were excluded from the meta-analysis if the out-
comes of interest were not reported for both groups, or
solid tumours were considered, or there was a consider-
able overlap between authors, centres or patient cohorts
evaluated.
Outcomes of Interest
Primary outcomes analysed were: overall survival (OS)
and disease free survival (DFS). Secondary outcomes
measured were: recurrence rate and mortality.
Measures of treatment effect
Statistical analysis for categorical variables was performed
by using the odds ratio (OR). This ratio represents the
odds of an adverse event occurring in the surgical treat-
ment group compared with the medical treatment group.
The Mantel-Haenszel method was used to combine the
ORs for the outcomes of interest. Intention-to-treat ana-
lyses were performed extracting the number of patients
originally allocated to each treatment group irrespective
of compliance. Results were presented on a forest plot
graphs.
Assessment of heterogeneity
Heterogeneity was first tested using Chi-squared test. A
Chi-squared test with a P value < 0.100 representing statis-
tical significance. However, since tests of heterogeneity
had a relative low power when there were few study we
further explored heterogeneity derived from another sta-
tistical method named “inconsistency” or I
2 metric, which
is independent of the number of combined studies. If I
2 is
equal 0%, there is no heterogeneity. If I
2 > 50% heteroge-
neity is indicated.
Results for the meta-analysis
Eligible Studies
Using the search strategy listed above, 114 publications
were identified. Fifty-two studies were excluded following
title and abstract review. The remaining 62 studies were
investigated in detail and 57 studies were excluded as
they did not meet the inclusion criteria for this review
(Figure 1).
There were 1 RCT and 4 non-randomised prospective
controlled studies comparing surgical versus medical treat-
ment for PGIL, which fulfilled the inclusion criteria and
were analysed in the systematic review (Table 1) [6,8-11].
Seven hundred and one patients were analysed, divided
into two groups: 318 who underwent to surgery alone or
associated with chemotherapy and/or radiotherapy (surgi-
cal group) versus 383 who were treated with chemother-
apy and/or radiotherapy (medical group). Only in the
randomised trial [8] the patients were divided in three dif-
ferent group: surgery (80 patients), radiotherapy (78
patients) and chemotherapy (83 patients).
Results of Meta-analysis
Despite the OS at 10 years between surgical and medical
groups did not show relevant differences (P = 0.25)
(Figure 2), the DFS was significantly better in the medical
group (P = 0.00001) (Figure 3). Despite not statistically sig-
nificant, a trend was noticed in the recurrence rate, which
was lower in the medical group (6.06 vs. 8.57%) (P = 0.63)
(Figure 4). Furthermore the recurrences after surgical
treatment were associated with higher mortality (50% vs.
0%) (P = 0.10) (Figure 5). Similarly an higher mortality
was revealed in the surgical group (4.51% vs. 1.50%) (P =
0.29) (Figure 6).
Discussion
Based on the assumption that PGIL is a localised dis-
ease, the surgical treatment was traditionally considered
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impressive results in terms of long DFS and OS
[3,12-16].
Nowadays this approach has been extensively revised
and the management of PGIL is centred on systemic
treatments such as chemo- and radiotherapy.
The current National Comprehensive Cancer Network
(NCCN) guidelines [17,18] suggests for the gastric MALT
lymphoma chemotherapy mainly and Helicobacter pylori
eradication therapy in the early stage. Surgery is restricted
to the treatment of complications, such as occlusion,
bleeding or perforation. Preventive surgery is sometime
advocated in bulky tumours, when rapid tumour necrosis
secondary to chemo-/radiotherapy may be associated with
a high risk of life threatening complications. Surgery is
also required for removal of residual disease after medical
debulking [19]. Total gastrectomy is the most frequent
procedure performed for gastric MALT lymphomas, given
the evidence that they are multicentric; a D2 lymphade-
nectomy is recommended [20].
The majority of small bowel lymphomas are represented
by B-large cell lymphomas. The NCCN guidelines pro-
poses surgery or radiotherapy as equally effective in the
early stage of MALT lymphomas, while chemotherapy for
B-large cell lymphomas and advanced stage of MALT lym-
phomas. In locally advanced lymphomas of the small
bowel, surgical resection is indicated during laparotomy/
laparoscopy for tumours of undefined histology or compli-
cated by intestinal occlusion, bleeding, and perforation.
Surgery may be advocated before chemotherapy in bulky
Records identified through database 
searching 
(n = 145) 
Additional records identified through 
other sources 
(n = 0) 
Records after duplicates removed 
(n = 31) 
Records screened 
(n =114) 
Records excluded by title or abstract 
(n = 52) 
Full-text articles assessed for 
eligibility 
(n = 62) 
Full-text articles excluded 
(n = 57) 
Not comparing chemo-/radio-therapy and surgery 
No outcomes of interest were reported  
Including solid tumors 
Overlap between authors, centers and patient cohorts  
Review or Protocol only  
Studies included in 
qualitative synthesis 
(n = 5) 
Studies included in 
quantitative synthesis  
(meta-analysis) 
(n = 5) 
Figure 1 Study selection flow chart.
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Page 3 of 7Table 1 Characteristics of the included studies
Author/
Year
Types of
study
N° of total
evaluated
patients
Inclusion criteria Surgical
treatment +/-
medical
theraphy
Medical theraphy
alone
Mean
follow-
up
Results
Overall
survival
Event-free
survival
Avilés et
al. [8]
2005
RCT
Open-label
241 Patients with low-grade gastric MALT lymphoma age < 70 yr old, no
gender difference, ECOG status ≤2, immunodeficiency virus test negative,
tumor mass > 5, previously untreated, stage I or IIE (according to the
Lugano Conference criteria)
80 patients
received surgery
alone
(total
gastrectomy)
78 patients received
only radiotherapy
83 patients received
only chemotherapy
7, 5
years
(range
4.8-11.6
yr)
10 years
80% S
group
75% R
group
85% C
group
10 years
52% S
group
52% R
group
87% C
group
Gobbi et
al. [10]
2000
PNR 154 Patients who fulfilled Lewin’s criteria for diagnosing PGL (stomach and
intestinal). Low-grade MALT lymphomas were excluded from this study
106 patients
received
chemotherapy
plus surgery
48 patients received
chemotherapy
Radiotherapy was
optionally given only
when residual
tumor masses seemed
to persist at restaging
after primary
therapy or when
bulky masses were
present at onset.
NI NI NI
Popescu
et al. [9]
1990
PNR 37 Patients with a histological diagnosis of intermediate or high-grade NHL
according to the Working Formulation (WF) involving the stomach were
included. Patients who received radiotherapy but no chemotherapy
treatment were not included.
Patients in whom lymphoma diagnosis predated demonstration of gastric
involvement or where the bulk of the disease and its manifestations was
extra-abdominal, nodal, hepatic or splenic were considered to have
secondary involvement of the stomach were excluded.
13 Surgery and
chemotherapy
5 total
gastrectomy
8 partial
gastrectomy
24 patients received
chemotherapy alone
53
months
5 years
60% in S+C
group
67% in
medical
therapy
group
5 years
85 > % %
in S+C
group
62% in
medical
therapy
group
Binn et
al. [11]
2003
PNR
Multicentric
84 Patients with diffuse large B-cell
primary gastric lymphoma with stage IE and IIE according to the Ann Arbor
staging system. Mediterranean lymphoma, human immunodeficiency virus-
related lymphoma and post-transplantation
lymphoma were not included.
40 patients
received surgery
plus
chemotherapy
21 total
gastrectomy
19 partial
gastrectomy
44 patients received
chemotherapy alone
7 patients received
additional
radiotherapy
59
months
(range
3-128)
5 years
90, 5% in S
+C group
91, 1% in
medical
therapy
group
5 years
85, 5% in S
+C group
91, 6% in
medical
terapy
group
Koch et
al. [6]
2001
PNR
Multicentric
185 Patients with all histological tips of gastric low and high grade lymphoma
but only in stage I E and II E 1- 2.
Patients who were older than 75 years and/or presented with second
malignancies,
had missing confirmation of histologic subtype by central review, or had
comorbidity prohibiting therapy were excluded from study
79 patients
received
complete or
partial resection
in combination
with
radio- and/or
chemotherapy
106 patients received
only radio- and/or
chemotherapy
52
months
(range
0-92
months)
5 years
84, 2% in
medical
therapy
group
82%
Combined
surgical
treatment
5 years
78.7% in
medical
therapy
group
78, 9%
Combined
surgical
treatment
RCT = randomised clinical trial; PNR = prospective non randomised; NI = not indicated; S = surgery; R = radiotherapy; C = chemotherapy
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7lesions in order to prevent bowel perforation. A segmental
intestinal resection with the own mesentery containing at
least 12 lymph nodes is recommended.
In the colon-rectum localization, the MALT lympho-
mas are more common. The NCCN proposed for the
colon the same protocols as for the small intestine.
In this cases the surgical approach is represented by the
segmental resection of the colon, or a local excision for
rectal tumours.
The MALT lymphomas represent the majority of PGIL
[21], therefore the disease stage is commonly IE [6] with
a favourable prognosis [21].
Given the actual dominant role of chemotherapy in the
treatment of PGIL, in our literature research most of out-
comes resulted from combined therapy. We could iden-
tify only one trial [8] analysing surgery, radiotherapy and
chemotherapy separately. Int h i st r i a l ,A v i l e se ta l
included only patients with diagnosis of low-grade gastric
MALT lymphoma, who were randomised to be treated
with primary surgical resection (total gastrectomy and
D2 limphadenectomy), radiotherapy or chemotherapy. At
4 weeks complete response was achieved in all patients,
but relapse in another abdominal site were more frequent
in patients treated with surgery or radiotherapy. At 10
years DFS and OS were statistical significantly higher in
the chemotherapy group (p = 0.01 and p = 0.04).
Surgery lost its leading role, becoming the treatment of
choice only in acute complicated cases or in the preven-
tion of chemotherapy and/or radiotherapy related compli-
cations secondary to rapid tumour necrosis [22]. The aim
of preventive surgery is to reduce the high incidence of
severe morbidity and mortality due to an emergency lapar-
otomy in highly compromised patients [23]. In the past
this risk was overestimated and a surgical management
was more frequently advocated; actually it stands at 5%
[24]: surgery has more than 5% of procedure related mor-
bidity [25] and similarly, from our meta-analysis resulted a
higher mortality (P = 0, 29). Therefore surgery must be
reserved to very selected patients.
One of the main limitations of our study is the retro-
spective nature of the majority of studies included in the
systematic review. These studies are heterogeneous, com-
bining different types of malignant lymphoma, using dif-
ferent histology classifications and staging systems.
Moreover, the aim of this review was the comparison of
surgery versus medical therapies but only one study con-
fronted these two approaches. In the others studies, sur-
gery was part of a multimodal treatment, associated to
chemo with or without radiotherapy. Besides, case history
considers different type of lymphomas, in different stages,
with different prognosis, without stratification. Therefore,
the application of selective methods and statistical analysis,
Figure 2 The overall survival at 10 years in patients with PGIL treated with chemo and/or radiotherapy versus the surgical approach
associated with adjuvant treatments. Surgical Group (SG): surgery alone or associated with chemotherapy and/or radiotherapy. Medical Group
(MG): chemotherapy and/or radiotherapy.
Figure 3 The disease free survival at 10 years in patients with PGIL treated with chemo and/or radiotherapy versus the surgical
approach associated with adjuvant treatments. Surgical Group (SG): surgery alone or associated with chemotherapy and/or radiotherapy.
Medical Group (MG): chemotherapy and/or radiotherapy.
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ally accepted, they cannot bring to evidence based
conclusions.
It would be interesting to analyze only studies including
surgery during not surgical treatments in order to evaluate
if, when and why surgery was used. From this type of ana-
lysis prognostic factors for development of acute compli-
cations could be evident and could help selecting high risk
patients that are preemptively candidate for surgery.
Conclusions
Although from our meta-analysis there was not any signif-
icant difference in terms of OS between surgical and medi-
cal groups, DFS was significantly better in the medical
group. Accordingly a lower recurrence rate was reported
in the medical group. Moreover, our meta-analysis showed
an higher mortality in the surgical group. This confirms
the widely recognized primary role of the chemotherapy,
as part of systemic treatment in the medical group.
Figure 4 The incidence of recurrences in patients with PGIL treated with chemo and/or radiotherapy versus the surgical approach
associated with adjuvant treatments. Surgical Group (SG): surgery alone or associated with chemotherapy and/or radiotherapy. Medical Group
(MG): chemotherapy and/or radiotherapy.
Figure 5 The mortality in patients with recurrence from PGIL treated with chemo and/or radiotherapy versus the surgical approach
associated with adjuvant treatments. Surgical Group (SG): surgery alone or associated with chemotherapy and/or radiotherapy. Medical Group
(MG): chemotherapy and/or radiotherapy.
Figure 6 The mortality in patients with PGIL treated with chemo and/or radiotherapy versus the surgical approach associated with
adjuvant treatments. Surgical Group (SG): surgery alone or associated with chemotherapy and/or radiotherapy. Medical Group (MG):
chemotherapy and/or radiotherapy.
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acutely complicated, although there is no evidence in
literature regarding the utility of preventive surgery.
Despite the absence in literature of high quality studies
(RCT) demonstrating the effectiveness of chemotherapy
without local surgical resection in patient with PGIL, the
evidence present in literature and analyzed in our review
well support a systemic approach for PGIL patients.
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